Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer.
Edwards DM, Schonewolf CA, Rice JD, Schipper M, Haken RKT, Matuszak M, Balter J, Jarema D, Arenberg DA, Piert M, Qin A, Kalemkerian GP, Schneider BJ, Ramnath N, Chapman CH, Elliott DA, Lawrence TS, Hearn J, Hayman JA, Jolly S. Edwards DM, et al. Among authors: kalemkerian gp. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1332-1343. doi: 10.1016/j.ijrobp.2024.06.018. Epub 2024 Jul 4. Int J Radiat Oncol Biol Phys. 2024. PMID: 38971385 Clinical Trial.
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Kim HR, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Santorelli ML, Pietanza MC, Rudin CM. Kim HR, et al. Among authors: kalemkerian gp. JTO Clin Res Rep. 2023 Sep 9;4(11):100572. doi: 10.1016/j.jtocrr.2023.100572. eCollection 2023 Nov. JTO Clin Res Rep. 2023. PMID: 37954964 Free PMC article.
Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
Khurshid H, Ismaila N, Bian J, Dabney R, Das M, Ellis P, Feldman J, Hann C, Kulkarni S, Laskin J, Manochakian R, Mishra DR, Preeshagul I, Reddy P, Saxena A, Weinberg F, Kalemkerian GP. Khurshid H, et al. Among authors: kalemkerian gp. J Clin Oncol. 2023 Dec 10;41(35):5448-5472. doi: 10.1200/JCO.23.01435. Epub 2023 Oct 11. J Clin Oncol. 2023. PMID: 37820295
Lung Cancer in Armenia.
Zohrabyan D, Karapetyan N, Danielyan S, Saghatelyan T, Safaryan L, Bardakhchyan S, Tamamyan G, Harutyunyan M, Rushanyan M, Mkrtchyan G, Badalyan S, Avagyan A, Harutyunyan L, Lazaryan A, Mkhitaryan S, Khanoyan A, Sargsyan A, Mailyan M, Mamunts D, Asadyan A, Khachatryan P, Mkhitaryan A, Kalemkerian GP. Zohrabyan D, et al. Among authors: kalemkerian gp. J Thorac Oncol. 2023 Apr;18(4):402-409. doi: 10.1016/j.jtho.2022.12.015. J Thorac Oncol. 2023. PMID: 36990573 Free article. No abstract available.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Griesinger F, et al. Among authors: kalemkerian gp. Ann Oncol. 2022 Nov;33(11):1168-1178. doi: 10.1016/j.annonc.2022.08.002. Epub 2022 Aug 13. Ann Oncol. 2022. PMID: 35973665 Free article. Clinical Trial.
143 results